Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-017-0081-5
Abstract: Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX… read more here.
Keywords: steroid sparing; sparing agent; versus host; agent chronic ... See more keywords